

POSTER PRESENTATION

Open Access

# Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

Sara Labiano<sup>1\*</sup>, Asis Palazon<sup>1</sup>, Elixabet Bolaños-Mateo<sup>1</sup>, Arantza Azpilicueta<sup>1</sup>, Alfonso Rodriguez<sup>1</sup>, Aizea Morales-Kastresana<sup>1</sup>, Elena Marin<sup>1</sup>, Alfonso Gurpide<sup>2</sup>, Maria Rodriguez-Ruiz<sup>1</sup>, M Angela Aznar<sup>1</sup>, Maria Jure-Kunkel<sup>3</sup>, Ignacio Melero<sup>1</sup>

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

Hypoxia is a common feature in solid tumors that has been implicated in immune-evasion. Previous studies from our group have shown that hypoxia up-regulates the co-stimulatory receptor CD137 on activated T lymphocytes and on vascular endothelial cells. In this study, we show that exposure of mouse and human tumor cell lines to hypoxic conditions (1% O<sub>2</sub>) promotes CD137 transcription. However, the resulting mRNA is predominantly an alternatively spliced form that encodes for a soluble variant, lacking the transmembrane domain. Accordingly, soluble CD137 (sCD137) is detectable by ELISA in the supernatant of hypoxia-exposed cell lines and in the serum of tumor-bearing mice. sCD137, as secreted by tumor cells, is able to bind to CD137-Ligand (CD137L). Our studies on primed T lymphocytes in co-culture with stable transfectants for CD137L demonstrate that tumor-secreted sCD137 prevents co-stimulation of T lymphocytes. Such an effect results from preventing the interaction of CD137L with the transmembrane forms of CD137 expressed on T lymphocytes undergoing activation. This mechanism is interpreted as a molecular strategy deployed by tumors to repress lymphocyte co-stimulation via CD137/CD137L.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P218

Cite this article as: Labiano et al.: Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P218.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



**Authors' details**

<sup>1</sup>Immunology and Immunotherapy, Center for Applied Medical Research, Pamplona, Spain. <sup>2</sup>Oncology, CUN, Pamplona, Spain. <sup>3</sup>Oncology Drug Discovery division, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA.

<sup>1</sup>Immunology and Immunotherapy, Center for Applied Medical Research, Pamplona, Spain

Full list of author information is available at the end of the article